Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2026 | 1 | -$5.37 | -$5.37 | -$5.37 |
| Q2 2026 | 1 | -$0.69 | -$0.69 | -$0.69 |
| Q3 2026 | 1 | -$0.74 | -$0.74 | -$0.74 |
| Q4 2026 | 1 | -$0.77 | -$0.77 | -$0.77 |
| Q1 2027 | 1 | -$1.05 | -$1.05 | -$1.05 |
| Q2 2027 | 1 | -$0.62 | -$0.62 | -$0.62 |
| Q3 2027 | 1 | -$0.67 | -$0.67 | -$0.67 |
| Q4 2027 | 1 | -$0.70 | -$0.70 | -$0.70 |
Cns Pharmaceuticals Inc last posted its earnings results on Tuesday, March 31st, 2026. The company reported $-5.09 earnings per share for the quarter, missing analysts' consensus estimates of $-5.09 by $0. The company had revenue of 0 for the quarter and had revenue of 0 for the year. Cns Pharmaceuticals Inc has generated $-36 earnings per share over the last year ($-35.75 diluted earnings per share) and currently has a price-to-earnings ratio of -0.17. Cns Pharmaceuticals Inc has not formally confirmed its next earnings publication date, but the company's estimated earnings date is N/A based on prior year's report dates.
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 03/31/2026 | Q4 2025 | -$5.09 | -$10.15 | -5.06 | $0 | $0 |
| 11/14/2025 | Q3 2025 | -$6.63 | -$5.76 | 0.87 | $0 | $0 |
| 08/14/2025 | Q2 2025 | -$9.60 | -$6.42 | 3.18 | N/A | $0 |
| 05/15/2025 | Q1 2025 | N/A | -$18.93 | N/A | N/A | $0 |
| 03/31/2025 | Q4 2024 | N/A | -$26.96 | N/A | N/A | $0 |
| 11/14/2024 | Q3 2024 | -$0.10 | -$151.64 | -151.54 | N/A | $0 |
| 08/14/2024 | Q2 2024 | -$3,585.43 | -$4,031.54 | -446.11 | N/A | $0 |
| 05/15/2024 | Q1 2024 | N/A | -$12,205.00 | N/A | N/A | $0 |
| 04/01/2024 | Q4 2023 | -$57,000.00 | -$28,623.00 | 28377 | N/A | $0 |
| 11/14/2023 | Q3 2023 | -$51,900.00 | -$32,483.00 | 19417 | N/A | $0 |
| 08/14/2023 | Q2 2023 | -$84,600.00 | -$31,113.00 | 53487 | N/A | $0 |
| 05/15/2023 | Q1 2023 | N/A | -$77,607.00 | N/A | N/A | $0 |
| 03/31/2023 | Q4 2022 | -$6,000.00 | -$114,634.00 | -108634 | N/A | $0 |
| 11/10/2022 | Q3 2022 | -$2.40 | -$76,878.00 | -76875.6 | N/A | $0 |
| 08/12/2022 | Q2 2022 | -$2.40 | -$80,172.00 | -80169.6 | N/A | $0 |
| 05/13/2022 | Q1 2022 | N/A | -$2,192,778.00 | N/A | N/A | $0 |
| 03/03/2022 | Q4 2021 | -$18,909.45 | -$88,353.00 | -69443.55 | N/A | $0 |
| 11/12/2021 | Q3 2021 | -$18,909.45 | -$125,091.00 | -106181.55 | N/A | $0 |
| 08/13/2021 | Q2 2021 | -$14,407.20 | -$134,955.00 | -120547.8 | N/A | $0 |
| 05/13/2021 | Q1 2021 | N/A | -$131,850.00 | N/A | N/A | $0 |
The conference call for Cns Pharmaceuticals Inc's latest earnings report can be listened to online.
The conference call transcript for Cns Pharmaceuticals Inc's latest earnings report can be read online.
Cns Pharmaceuticals Inc (:CNSP) has a recorded net income of $-15,850,564.Cns Pharmaceuticals Inc has generated $-35.75 earnings per share over the last four quarters.
Cns Pharmaceuticals Inc (:CNSP) has a price-to-earnings ratio of -0.17 and price/earnings-to-growth ratio is -0.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED